← Leaderboards
Maria Hahn
Beckman Research Institute/City Of Hope
$2,043,163
Attributed
$4,086,325
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,086,325 · 2
By mechanism
R01$3,647,565 · 1
R21$438,760 · 1
Top collaborators
- John H Yim7 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- John H Yim$2,703,313
Others in their field
Other Emerging Leaders on “Cancer Diagnostics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$295,500,773
- Lynn Briscoe · Leidos Biomedical Research, Inc.$100,239,656
- Leonard Freedmand · Leidos Biomedical Research, Inc.$65,291,934
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,466,796
- John Freymann · Leidos Biomedical Research, Inc.$14,011,208
Research focus
Cancer DiagnosticsDiagnosticThyroid GlandBenignMolecular DiagnosticsMalignant NeoplasmsMalignant - DescriptorNoduleValidationEpigenomicsUnited StatesThyroid NoduleBiological MarkersMalignant Neoplasm Of ThyroidDna MethylationEpigenetic ProcessBiologicalDiagnostic AccuracyEvaluationMethylation PatternCytopathologyGene FusionEpigenetic MarkerGene Mutation
Grant awards (7)
Validation of epigenomic biomarkers for thyroid cancer diagnostics$819,119
R01 · FY2025 · CA · contact PI
Validation of epigenomic biomarkers for thyroid cancer diagnostics$779,408
R01 · FY2024 · CA · contact PI
Validation of Epigenomic Biomarkers for Thyroid Cancer Diagnostics$267,000
R01 · FY2024 · CA · contact PI
Validation of epigenomic biomarkers for thyroid cancer diagnostics$823,929
R01 · FY2023 · CA · contact PI
Validation of epigenomic biomarkers for thyroid cancer diagnostics$958,109
R01 · FY2021 · CA · contact PI
Epigenomic Biomarkers to Manage Thyroid Nodule Overdiagnosis and Overtreatment$196,127
R21 · FY2019 · CA · contact PI
Epigenomic Biomarkers to Manage Thyroid Nodule Overdiagnosis and Overtreatment$242,633
R21 · FY2018 · CA · contact PI